Cellectis S.A. American Depositary Shares CLLS
$3.10
-0.64%
at last close
Market Cap$314.24 million
P/E Ratio—
Div Yield—
Volume75.6K
52-Week Range
$2.35$5.48
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $8.67 (+179.6% upside)
Key Stats
- Today's Range
- $3.01 – $3.18
- 50-Day Range
- $2.35 – $3.60
- 52-Week Range
- $2.35 – $5.48
- Volume
- 76K shs
- Average Volume
- 21K shs
- Market Cap
- $314.24 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.26%
- Days to Cover
- 5.35
About Cellectis S.A. American Depositary Shares
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Related Stocks
Compare head-to-head: CLLS vs NVDA·CLLS vs AAPL·CLLS vs GOOGL·CLLS vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.